BenevolentAI has discovered a second novel target for idiopathic pulmonary fibrosis (IPF), which AstraZeneca has added to its drug development portfolio, resulting in a milestone payment to the Lon
A pooled analysis of data for AstraZeneca and Sanofi's respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at preventing lower respirat
AstraZeneca's SGLT2 inhibitor Farxiga has hit the mark in a phase 3 heart failure trial that brings it back into contention with its main rival Jardiance from Boehringer Ingelheim and Eli L
The FDA has kicked off a priority review of AstraZeneca's checkpoint inhibitor Imfinzi for biliary tract cancer (BTC), setting up what could be approval for an immunotherapy for the group o
AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology
